Lyra Therapeutics, Inc. (NASDAQ:LYRA – Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 29th, there was short interest totalling 160,200 shares, a decrease of 13.6% from the February 14th total of 185,400 shares. Based on an average daily trading volume, of 254,600 shares, the short-interest ratio is currently 0.6 days.
Hedge Funds Weigh In On Lyra Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its position in Lyra Therapeutics by 368.9% during the third quarter. Tower Research Capital LLC TRC now owns 6,762 shares of the company’s stock valued at $26,000 after purchasing an additional 5,320 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Lyra Therapeutics by 813.9% in the 1st quarter. JPMorgan Chase & Co. now owns 7,759 shares of the company’s stock worth $31,000 after acquiring an additional 6,910 shares during the last quarter. Heritage Wealth Management Inc. Texas bought a new stake in shares of Lyra Therapeutics in the 4th quarter worth about $52,000. Goldman Sachs Group Inc. bought a new stake in shares of Lyra Therapeutics in the 4th quarter worth about $68,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Lyra Therapeutics in the 3rd quarter worth about $73,000. Institutional investors own 80.20% of the company’s stock.
Lyra Therapeutics Price Performance
Shares of NASDAQ LYRA opened at $5.93 on Monday. The firm has a fifty day moving average price of $5.19 and a 200-day moving average price of $4.30. Lyra Therapeutics has a 1 year low of $1.86 and a 1 year high of $6.51. The stock has a market cap of $311.70 million, a PE ratio of -4.15 and a beta of 0.20.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on LYRA
Lyra Therapeutics Company Profile
Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
Featured Articles
- Five stocks we like better than Lyra Therapeutics
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
- What is an Earnings Surprise?
- 3 Large-Cap Stocks Buying Back Shares Aggressively
- 3 Best Fintech Stocks for a Portfolio Boost
- Kohl’s Makes Steady Inventory Improvements. Will Buyers Step In?
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.